Centredin en es it fr

Centredin Brand names, Centredin Analogs

Centredin Brand Names Mixture

  • No information avaliable

Centredin Chemical_Formula


Centredin RX_link


Centredin fda sheet

Centredin FDA

Centredin msds (material safety sheet)

Centredin MSDS

Centredin Synthesis Reference

M. Hartmann, L. Panizzon, U.S. Pat. 2,507,631 (1950)

Centredin Molecular Weight

233.306 g/mol

Centredin Melting Point


Centredin H2O Solubility


Centredin State


Centredin LogP


Centredin Dosage Forms

Tablets; Tablets (sustained release)

Centredin Indication

For use as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity.

Centredin Pharmacology

Methylphenidate is a central nervous system stimulant used most commonly in the treatment of attention-deficit disorders in children and for narcolepsy. Its mechanisms appear to be similar to those of dextroamphetamine.

Centredin Absorption

Readily absorbed in a biphasic manner. It reaches peak absorption at approximately two hours for the first phase and five hours for the second phase. Bioavailability is low (approximately 30%)

Centredin side effects and Toxicity

Symptoms of overdose include vomiting, agitation, tremors, hyperreflexia, muscle twitching, convulsions (may be followed by coma), euphoria, confusion, hallucinations, delirium, sweating, flushing, headache, hyperpyrexia, tachycardia, palpitations, cardiac arrhythmias, hypertension, mydriasis, and dryness of mucous membranes. LD50=190mg/kg (orally in mice)

Centredin Patient Information

Centredin Organisms Affected

Humans and other mammals